AstraZeneca in talks to shift COVID-19 vaccine production to Catalent factory

AstraZeneca Plc is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Baltimore plant to a factory owned by Catalent Inc, the New York Times reported, citing people familiar with the matter. The British drugmaker has been on the lookout for an alternative production site since the U.S. government stopped it from using Emergent BioSolutions Inc's Baltimore plant after workers accidentally contaminated a batch of Johnson & Johnson's vaccine with ingredients from AstraZeneca's that was also being produced at the time.